Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA approves new antibiotic to treat community-acquired bacterial pneumonia


SILVER SPRING, Md., Aug. 19, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

"This new drug provides another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease," said Ed Cox, M.D., M.P.H., director of FDA's Office of Antimicrobial Products. "For managing this serious disease, it is important for physicians and patients to have treatment options. This approval reinforces our ongoing commitment to address treatment of infectious diseases by facilitating the development of new antibiotics."

Community-acquired pneumonia occurs when someone develops pneumonia in the community (not in a hospital). Pneumonia is a type of lung infection that can range in severity from mild to severe illness and can affect people of all ages. According to data from the Centers from Disease Control and Prevention, each year in the United States, about one million people are hospitalized with community-acquired pneumonia and 50,000 people die from the disease.

The safety and efficacy of Xenleta, taken either orally or intravenously, was evaluated in two clinical trials with a total of 1,289 patients with CABP. In these trials, treatment with Xenleta was compared to another antibiotic, moxifloxacin with or without linezolid. The trials showed that patients treated with Xenleta had similar rates of clinical success as those treated with moxifloxacin with or without linezolid. 

The most common adverse reactions reported in patients taking Xenleta included diarrhea, nausea, reactions at the injection site, elevated liver enzymes and vomiting. Xenleta has the potential to cause a change on an ECG reading (prolonged QT interval). Patients with prolonged QT interval, patients with certain irregular heart rhythms (arrhythmias), patients receiving treatment for certain irregular heart rhythms (antiarrhythmic agents), and patients receiving other drugs that prolong the QT interval should avoid Xenleta. In addition, Xenleta should not be used in patients with known hypersensitivity to lefamulin or any other members of the pleuromutilin antibiotic class, or any of the components of Xenleta. Based on findings of fetal harm in animal studies, pregnant women and women who could become pregnant should be advised of the potential risks of Xenleta to a fetus. Women who could become pregnant should be advised to use effective contraception during treatment with Xenleta and for two days after the final dose.

Xenleta received FDA's Qualified Infectious Disease Product (QIDP) designation. The QIDP designation is given to antibacterial and antifungal drug products intended to treat serious or life-threatening infections under the Generating Antibiotic Incentives Now (GAIN) title of the FDA Safety and Innovation Act. As part of QIDP designation, Xenleta was granted Priority Review under which the FDA's goal is to take action on an application within an expedited time frame.

The FDA granted the approval of Xenleta to Nabriva Therapeutics.

A key global challenge the FDA faces as a public health agency is addressing the threat of antimicrobial-resistant infections. Among the FDA's other efforts to address antimicrobial resistance, is the focus on facilitating the development of safe and effective new treatments to give patients more options to fight serious infections.

More information:

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Alison Hunt, 240-402-0764, alison.hunt@fda.hhs.gov

SOURCE U.S. Food and Drug Administration


These press releases may also interest you

at 22:20
Genial Technology, Inc. is excited to announce the launch of GenialAItm OCR, a SaaS product that will reduce document processing costs while maintaining accuracy and security. The official launch date for GenialAItm OCR is July 9, 2020. As the...

at 21:05
Yamato Holdings Co., Ltd. ("Yamato") and Palantir Technologies Inc. ("Palantir") have announced the beginning of their work to accelerate the digital transformation ("DX") of the logistics industry by transforming Yamato's internal operations. Yamato...

at 21:01
The zebrafish has been utilised as a model organism for biomedical research globally for half a century, mainly due to the high genetic similarity (over 70%) between zebrafish and human genes, with over 80% of human morbid genes related to at least...

at 20:50
Aurora Spine Corporation ("Aurora Spine" or the "Company") announces financial results for the First Quarter 2020, ended March 31, 2020.  All figures are in U.S. dollars. To our Shareholders: Q1 2020 started strongly for the Company based on...

at 19:35
Technavio has been monitoring the artificial intelligence platforms market and it is poised to grow by USD 12.51 billion during 2020-2024, progressing at a CAGR of over 33% during the forecast period. The report offers an up-to-date analysis...

at 19:32
Duvora has introduced an AI-driven video platform dedicated to virtual luxury home tours as a new way to meet the needs of affluent home buyers in a post COVID-19 world....



News published on 19 august 2019 at 15:11 and distributed by: